ImmunityBio, Inc. (IBRX)

ImmunityBio, Inc. (IBRX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, IBRX's 50-day simple moving average broke out above its 200...

Biotech stocks are incredibly risky but can provide investors with huge returns since insurers in the U.S. will pay tremendous amounts for successful treatments. In the last few months in particular, ...

Structure Therapeutics' weight-loss drug candidate is attracting attention over excitement about obesity treatments. ImmunityBio rallied on hopes that its bladder cancer drug will now be better unders...

ImmunityBio, Inc.'s drug Anktiva received a Complete Response Letter, or CRL, from the FDA, delaying its approval for the treatment of NMIBC. The CRL was related to deficiencies in the FDA's inspectio...

Penny stocks, typically defined as stocks trading under $5 per share, offer traders massive upside profit potential but also higher risk due to greater volatility. When penny stocks become heavily sho...

The clinical-stage biotech's lead therapy is in trials to treat bladder cancer. The sale of company stock helped raise $470 million.

After I spent many years following Wall Street, there are a few characteristics about the “big money”  that stand out for me. One of these traits is that many if not most large investors are very relu...

American drug makers can generate gigantic profits, pushing their stock prices to great heights. The pharmaceutical sector is lucrative in general around the globe, while the space is very profitable ...

ImmunityBio is a clinical-stage biotech company. The company's lead therapy candidate is Anktiva.

The FDA rejected the Anktiva marketing application last month. Since the troubles lie with an outside organization, the company has no control over the resolution. The drug is good, so resubmission, a...